Zenas BioPharma Management
Management criteria checks 0/4
Zenas BioPharma's CEO is Lonnie Moulder, appointed in Aug 2023, has a tenure of 2.17 years. total yearly compensation is $20.00M, comprised of 2.1% salary and 97.9% bonuses, including company stock and options. directly owns 0.63% of the company’s shares, worth $5.58M. The average tenure of the management team and the board of directors is 1.6 years and 2.9 years respectively.
Key information
Lonnie Moulder
Chief executive officer
US$20.0m
Total compensation
| CEO salary percentage | 2.15% |
| CEO tenure | 2.2yrs |
| CEO ownership | 0.6% |
| Management average tenure | 1.6yrs |
| Board average tenure | 2.9yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | -US$177m |
| Mar 31 2025 | n/a | n/a | -US$163m |
| Dec 31 2024 | US$20m | US$430k | -US$157m |
| Sep 30 2024 | n/a | n/a | -US$129m |
| Jun 30 2024 | n/a | n/a | -US$87m |
| Mar 31 2024 | n/a | n/a | -US$46m |
| Dec 31 2023 | US$3m | US$127k | -US$37m |
Compensation vs Market: Lonnie's total compensation ($USD20.00M) is above average for companies of similar size in the US market ($USD3.56M).
Compensation vs Earnings: Lonnie's compensation has increased whilst the company is unprofitable.
CEO
Lonnie Moulder (68 yo)
Mr. Leon Oliver Moulder, Jr. also known as Lonnie, is Chairman of the Board of Zenas BioPharma, Inc since 2020 and Chief Executive Officer since August 2023. Mr. Moulder, Jr., also known as Lonnie, M.B.A.,...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman of the Board | 2.2yrs | US$20.00m | 0.63% $ 5.6m | |
| COO & President | 3.7yrs | US$6.00m | 0% $ 0 | |
| Chief Business Officer & CFO | 1.8yrs | US$4.84m | 0% $ 0 | |
| Chief Commercial Officer | 1.3yrs | US$5.89m | no data | |
| Chief Scientific Officer | less than a year | no data | no data | |
| Chief Legal Officer | 1.1yrs | no data | no data | |
| Chief Human Resources Officer | 1.6yrs | no data | no data | |
| Head of Research & Development and Chief Medical Officer. | 2yrs | US$1.72m | no data | |
| Head of Research & Development and Chief Medical Officer | less than a year | no data | no data |
Experienced Management: ZBIO's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman of the Board | 5.8yrs | US$20.00m | 0.63% $ 5.6m | |
| Independent Director | 2.9yrs | US$494.98k | no data | |
| Independent Director | 1.4yrs | US$493.67k | no data | |
| Independent Director | 1.7yrs | US$564.41k | 0% $ 0 | |
| Independent Director | 3.8yrs | US$511.50k | 0% $ 0 | |
| Independent Director | 2.9yrs | US$492.50k | 0.14% $ 1.2m | |
| Independent Director | 2.9yrs | US$494.98k | no data | |
| Independent Director | 5.1yrs | US$492.50k | no data |
Experienced Board: ZBIO's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/03 14:09 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zenas BioPharma, Inc. is covered by 8 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yigal Nochomovitz | Citigroup Inc |
| Yatin Suneja | Guggenheim Securities, LLC |
| Matthew Caufield | H.C. Wainwright & Co. |